Pictet & Cie (Europe) Sa Castle Biosciences Inc Transaction History

Pictet & Cie (Europe) Sa

$3.81 Billion
Q1 2024

A detailed history of Pictet & Cie (Europe) Sa transactions in Castle Biosciences Inc stock. As of the latest transaction made, Pictet & Cie (Europe) Sa holds 12,897 shares of CSTL stock, worth $280,767. This represents 0.01% of its overall portfolio holdings.

Number of Shares

12,897

Previous 13,563 4.91%

Holding current value

$280,767

Previous $292,000 2.4%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$18.06 - $25.3 $12,027 - $16,849	-666 Reduced 4.91%	12,897 $285,000
Q4 2023 Feb 09, 2024	SELL	$12.19 - $22.43 $6,290 - $11,573	-516 Reduced 3.67%	13,563 $292,000
Q3 2023 Nov 02, 2023	BUY	$13.28 - $20.3 $24,076 - $36,803	1,813 Added 14.78%	14,079 $237,000
Q2 2023 Aug 08, 2023	SELL	$11.66 - $26.0 $5,526 - $12,324	-474 Reduced 3.72%	12,266 $168,000
Q1 2023 May 01, 2023	BUY	$19.47 - $28.49 $2,375 - $3,475	122 Added 0.97%	12,740 $289,000

Q4 2022 Feb 08, 2023	SELL	$18.08 - $30.0 $60,369 - $100,170	-3,339 Reduced 20.92%	12,618 $0
Q3 2022 Nov 10, 2022	BUY	$22.51 - $34.32 $359,192 - $547,644	15,957 New	15,957 $416 Million
Q2 2022 Aug 05, 2022	SELL	$16.0 - $45.99 $171,584 - $493,196	-10,724 Closed	0 $0
Q1 2022 May 04, 2022	BUY	$33.17 - $46.98 $34,330 - $48,624	1,035 Added 10.68%	10,724 $481,000
Q4 2021 Feb 02, 2022	BUY	$39.06 - $67.58 $41,598 - $71,972	1,065 Added 12.35%	9,689 $415,000
Q3 2021 Nov 10, 2021	SELL	$60.13 - $77.6 $45,819 - $59,131	-762 Reduced 8.12%	8,624 $573,000
Q2 2021 Aug 11, 2021	BUY	$50.07 - $76.78 $63,388 - $97,203	1,266 Added 15.59%	9,386 $688,000
Q1 2021 May 10, 2021	BUY	$58.92 - $97.33 $478,430 - $790,319	8,120 New	8,120 $556,000

Others Institutions Holding CSTL

# of Institutions

162

Shares Held

25.3M

Call Options Held

82.2K

Put Options Held

150K

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $572M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pictet & Cie (Europe) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Pictet & Cie (Europe) Sa with notifications on news.

Account

Pictet & Cie (Europe) Sa Castle Biosciences Inc Transaction History